JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
HCT116 and COLO205 cells
Reaction Conditions
10 or 50 μg/mL fexofenadine for 18 or 24 h incubation
Applications
Fexofenadine (24 h incubation) significantly inhibited the upregulated expression of IL-8 in HCT116 and COLO205 cells stimulated with TNF-α. Fexofenadine (18 h incubation) also suppressed nuclear factor-κB DNA-binding activity in TNF-α-stimulated HCT116 cells.
Animal models
C57BL/6NCrljBgi female mice, 6 ~ 7 weeks old
Dosage form
2 or 10 mg/kg
Once daily by oral gavage
Oral administration of fexofenadine (2 or 10 mg/kg) reduced severity of colitis and phospho-IκB kinase activation in a mouse model of colitis induced by dextran sulfate sodium. These results suggest that fexofenadine is a potential therapeutic agent for the treatment of inflammatory bowel disease.
Note
The technical data provided above is for reference only.
References:
1. Koh SJ, Kim JW, Kim BG, et al. Fexofenadine regulates nuclear factor-κB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates acute and chronic colitis in mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352(3): 455-461.